The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
 
Daniel V.T. Catenacci
Honoraria - Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Genmab; Gritstone Bio; Guardant Health; Lilly; Merck; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Genentech/Roche; Guardant Health; Lilly; NantWorks
Research Funding - Genentech; OncoPlex Diagnostics
 
Haeseong Park
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst); Vertex (Inst)
 
A. Craig Lockhart
Research Funding - Bayer (Inst); CTI (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Macrogenics (Inst); Millennium (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teva (Inst); Vertex (Inst); Zenyaku Kogyo (Inst)
 
Philip Jordan Gold
No Relationships to Disclose
 
Peter C. Enzinger
Consulting or Advisory Role - Five Prime Therapeutics; Merck
 
Jeffrey L. Nordstrom
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
 
Sam Hong
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
 
Ronan Joseph Kelly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Clovis Oncology; EMD Serono; Gritstone Bio; Lilly; Novartis; OncoMed
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Research Funding - Advaxis; Bristol-Myers Squibb; Genentech/Roche; Macrogenics; Merrimack; Threshold Pharmaceuticals
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Sang Cheul Oh
No Relationships to Disclose
 
Se Hoon Park
No Relationships to Disclose
 
Yeul Hong Kim
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Macrogenics (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst)
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - LSK Biopharma
 
Keun-Wook Lee
Consulting or Advisory Role - Merck KGaA; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Matthew CH Ng
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology
Research Funding - ASLAN Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Taiho Pharmaceutical
 
Jon M. Wigginton
Employment - Macrogenics
Leadership - Macrogenics
Stock and Other Ownership Interests - Macrogenics
 
Jan Kenneth Davidson-Moncada
Employment - Macrogenics
Stock and Other Ownership Interests - Macrogenics
Travel, Accommodations, Expenses - Macrogenics
 
Yung-Jue Bang
Consulting or Advisory Role - Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)